Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025
Recursion Pharmaceuticals (RXRX) closed Friday at $4.17, up 8.31%, with volume near 33 million shares and trading near its 52-week low. MarketBeat reports a consensus “Hold” rating, with a $7.25 average price target and Q3 revenue down 80% year-on-year. Kingsview Wealth Management increased its RXRX stake by over 500% in Q2. About 89% of shares are institutionally held.